How India’s Pharmaceutical Industry Supports Healthcare Affordability

India’s pharmaceutical industry is often called the “pharmacy of the world.” It supplies affordable, high-quality medicines both home and abroad. The sector has grown into a global powerhouse. It now accounts for a large share of India’s manufacturing and exports. For example, it ranks 3rd globally by volume of drugs produced and 14th by value. It contributes ~1.72% to India’s GDP. The industry drives foreign exchange earnings through medicines and vaccines. In FY24, India’s drug exports reached ~Rs. 2,35,683 crore (US$ 27 billion). In 2023, it generated ~Rs. 1,65,851 crore (US$ 19 billion) in trade surplus. It also supports millions of jobs. In total, ~2.7 million people work in pharmaceuticals directly or indirectly. All these contributions help make healthcare more affordable and available.

India supplies 20% of the global demand for generics. Its generics and vaccines reach more than 200 countries. Millions of global patients rely on Indian-made medicines because of their low cost. Domestically, the industry has helped millions access essential treatments cheaply. It provides the medicines used in government health programmes and private hospitals alike.

Historical development of India’s pharma sector

The Indian pharmaceutical industry has a long history, which was only modernised after independence. Initially, India depended on foreign companies and imported medicines. When India gained independence in 1947, the pharma industry was small and technologically underdeveloped. The industry gradually accumulated capacity over the next decades. The turning points were the Drug Policy of 1978 and the Patents Act of 1970. They eliminated drug patents, and Indian companies were able to produce generic versions of older drugs. This policy made medicines much cheaper and let domestic companies grow.

The actual change was in the 1980s and 1990s. The industry was modernised and opened to international trade in that period. New processes and quality standards were implemented in companies. In 1991, the government opened its economy, and this enabled increased private investment in pharmaceuticals. Indian firms began exporting drugs. By the early 2000s, the industry had gained strong momentum. It was meeting rising domestic demand and expanding exports. In those years, India emerged as a leading global supplier of affordable medicines, helping to treat diseases like HIV/AIDS with low-cost generics.

By the 2010s, India was well known as the “pharmacy of the world”. It ranked globally behind only China and USA in volume terms. It built world-class manufacturing facilities and an industry ecosystem. Generics and vaccines made in India saved money for patients at home and abroad. For example, Indian firms supplied life-saving HIV drugs and vaccines that earned India praise for its role in global health.

In recent years, growth has continued. The Indian pharma market was valued at ~Rs. 4,80,095 crore (US$ 55 billion) in 2023. Industry associations and government reports project it will grow to Rs. 10,47,480- 11,34,770 crore (US$ 120-130 billion) by 2030. Exports have been growing steadily, reaching Rs. 2,35,683 crore (US$ 27 billion) in 2023. This growth reflects decades of capacity building. India’s status as a major generics maker is now firmly established. The industry’s history from traditional practices to a modern powerhouse shows how far it has come.

Domestic role in enhancing affordability

India’s pharma industry plays a central role in making healthcare affordable for Indians. Because many people pay out of pocket for medical care, low drug prices are critical. Indian companies keep prices competitive through economies of scale. The large domestic market and mass production allow companies to produce at low cost. This keeps prices lower than in many other countries. For example, Indian drug makers have cut prices on important medicines and offer patient assistance programmes. One analysis notes that most Indians struggle to afford medicines, and Indian firms step in by offering cheaper alternatives.

A key domestic initiative is the Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP). This government programme funds branded generic outlets that sell medicines at steep discounts. According to the Ministry of Chemicals & Fertilisers, by early 2025 there were over 15,000 Jan Aushadhi Kendras across India. These stores sell quality generic medicines at 80-90% lower than branded equivalents. So far, consumers have saved over Rs. 30,000 crore (US$ 3.44 billion) on medicines through these stores. The government plans to expand the network to ~25,000 centres by 2027, to reach even remote districts. This ensures affordable drugs get to underserved areas.

Private companies also help. Many firms produce generic drugs and biosimilars. Generic versions of off-patent drugs cost much less than the original brands. Biosimilars are follow-on versions of complex biological medicines, which are also cheaper. By developing and selling these low-cost alternatives, Indian companies make treatments accessible to more people.

The industry is also reaching patients through partner networks. For instance, smaller distributors use franchise models (like PCD pharma franchises) and third-party manufacturing to ensure medicines penetrate rural markets. These business models give small wholesalers and retailers access to affordable stock. Indian manufacturers provided vaccines and other essential drugs at no or low cost under government initiatives during COVID-19, which contributed to the reduction of the spread of the disease. In addition to the sale of medicine, pharmaceutical firms in India contribute to the health programmes of the population.

Beyond selling medicine, Indian pharmaceutical companies support public health initiatives. They provide or develop drugs and vaccines used in government programmes. For example, the industry supplies low-cost medicines under Ayushman Bharat, India’s national health insurance scheme for the poor. Thanks to affordable drugs, Ayushman Bharat has extended healthcare to over 600 million people. Many state vaccination drives also use locally made vaccines, which cost less than imports. In short, Indian pharma keeps drug prices down through generics, smart manufacturing, and by supporting government health schemes, thus easing the burden on patients and families.

Conclusion

India’s pharmaceutical sector has transformed over decades to become a pillar to national health and the global drug supply. The industry’s production of generic and specialty medicines has kept costs down and saved patients and governments enormous sums. With government schemes like Jan Aushadhi and PLI, India has built a robust system that prioritises affordable access. Domestic patients benefit from low prices, and poorer countries benefit from India’s exports. As a result, millions receive essential treatments than would otherwise be possible.

However, challenges remain. The health system requires additional investments and extended insurance. India needs to keep on enhancing its quality cheques, promote innovation and make sure that remote and low-income people access these affordable medicines. India can spread the benefits of its pharma revolution by filling regulatory and infrastructural lapses, and by establishing industry-government alliances.

In the future, India is poised to enhance its leadership in the world. The bright future is projected by the domestic market of up to US$ 120-130 billion and the export potential of up to US$ 350 billion by 2047. India will improve its economy and contribute to countries getting healthier in case the policies remain in favour of research, manufacturing, and fair access.

The journey from humble beginnings to “pharmacy of the world” has shown what Indian industry and policy together can achieve. By maintaining this momentum and focusing on patient needs first, India’s pharmaceutical sector will keep driving healthcare affordability for all.